drugset
drugset / Trial / NCT00492830

Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00492830 ↗

Phase 1 Completed 19 enrolled Tracon Pharmaceuticals Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.

Timeline

Start
2007-06
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject TRC093 Monoclonal antibody — Intravenous

Indications

cancer metastatic neoplasm